CJC-1295: Chemical Properties
10 Citas PubMedRevisado por EspecialistasCertificado GMPÚltima Revisión: abril de 2026
Propiedades Químicas
| Molecular Formula | C165H271N47O46S |
| Molecular Weight | ~4562 g/mol |
| CAS Number (With DAC) | 2093839-18-8 |
| CAS Number (No-DAC / Mod GRF 1-29) | 863288-34-0 |
| Sequence (Backbone) | Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg(DAC)-NH2 |
| DAC Linker | N-ε-3-maleimidopropionyl (MPA) at Lys29 → covalent bond with serum albumin Cys-34 |
| Purity Standard | ≥98% by HPLC |
| Physical Form | Lyophilized white powder |
Identificadores
| Synonyms | CJC-1295, DAC:GRF, Somatocrinum |
| Distinction From No-DAC | CJC-1295 WITH DAC has an albumin-binding maleimide linker at Lys29; half-life 6–8 days. CJC-1295 No DAC (Mod GRF 1-29) has no such linker; half-life ~30 min. |
| IUPAC Core | 30-amino acid GRF[1-29] analogue with substitutions at positions 2 (Ala→D-Ala), 8 (Asn→Gln), 15 (Gly→Ala), 27 (Met→Leu), plus DAC linker at Lys29 |
| PubChem CID | Unspecified (related: CID 16133571) |
Referencias
- Jetté L, et al. (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 146(7):3052–3058.
- Ionescu M, Frohman LA. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab, 91(12):4792–4797.
- Teichman SL, et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab, 91(3):799–805.
- Alba M, et al. (2006). Once-monthly administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH-deficient dwarf rat. Am J Physiol Endocrinol Metab, 291(6):E1290–E1294.
- Walker RF. (2006). Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging, 1(4):307–308.
- Ben-Shlomo A, et al. (2020). Growth hormone-releasing hormone (GHRH) and its analogues: from bench to bedside. Neuroendocrinology, 110(3–4):192–199.
- Gahete MD, et al. (2009). In vivo and in vitro evidence for the importance of growth hormone-releasing hormone in the regulation of GH secretion. Mol Cell Endocrinol, 309(1–2):40–47.
- FDA. (2024). Bulk Drug Substances Under Evaluation for Use in Compounding Under Section 503A: Category 2. Docket FDA-2013-N-1525. Federal Register, Dec 2024.
- WADA. (2024). List of Prohibited Substances and Methods. S2: Peptide Hormones, Growth Factors, Related Substances, and Mimetics. World Anti-Doping Agency.
- Frohman LA, Jansson JO. (1986). Growth hormone-releasing hormone. Endocr Rev, 7(3):223–253.
Preguntas de Investigación Relacionadas
Desea la revisión completa de la investigación?
Ver Página Completa de Investigación de CJC-1295→SOLO PARA USO EN INVESTIGACIÓN
Este contenido se proporciona solo para fines educativos e informativos. Los productos se suministran exclusivamente para estudios in vitro y no son medicamentos, fármacos ni suplementos. No están aprobados por la FDA para prevenir, tratar o curar ninguna condición.